ii view: Rentokil starts saving money on mega deal
1st November 2022 11:26
by Keith Bowman from interactive investor
Its core pest control business is a largely non-discretionary essential service. Buy, sell, or hold?
Third-quarter update to 30 September
- Total revenue up 18.9% to £901.3 million
- Organic revenue up 6.2%
Chief executive Andy Ransom said:
"This has been another good quarter for Rentokil Initial. Supported by the essential nature of our services and ability to offset cost inflation through pricing, we continue to deliver both good growth and profitability, while retaining high levels of customer and colleague retention.”
ii round-up:
Pest control and hygiene provider Rentokil Initial (LSE:RTO) today detailed sales broadly in line with City forecasts, with annualised cost savings from its $6.7 billion (£5.8 billion) takeover of US rival Terminix expected to be between $20 million and $25 million by year end.
That’s around 15% of its previously forecast $150 million annualised costs savings and on track to achieve management's hoped-for 30% during its first year of completion. The purchase of Terminix more than doubles group headcount and adds significant new customer numbers to Rentokil’s base.
- Find out about: Trading Account | Share prices today | Top UK shares
Rentokil shares fell 3% in UK trading having gained 14% in October as the Terminix purchase completed. Coming into this latest update the shares were down by 7% year-to-date, broadly in line with the FTSE All Share index.
Rentokil’s total sales for the quarter to the end of September, including Terminix, gained 18.9% year-over-year to £901.3 million. Sales excluding acquisitions rose 6.2%, aided by an ability to pass on rising costs through price increases, although sales growth was down from 6.5% in the second quarter and 8.1% in Q1.
Acquisition adjusted sales for its core pest control business in North America rose by just 3.5% during the period, impacted by tough pandemic fuelled comparatives and hurricane Ian.
Pest control has historically generated just under two-thirds of Rentokil sales, hygiene services a further fifth, and its protect and enhance or landscaping and property care business the balance.
Rentokil’s full-year results are scheduled for 16 March.
ii view:
Founded in 1925 and headquartered in Crawley, Rentokil is today a FTSE 100 index constituent company with a stock market value of over £13 billion. Even prior to its takeover of Terminix, North America generated its biggest slug of sales at just over two-fifths, followed by the UK and Ireland and France at around a tenth each. It has purchased 43 smaller or bolt-on acquisitions in the year to date, most of them in pest control, bringing its bolt-on purchases to more than 200 businesses since 2016.
- Will November mark beginning of a new bull run?
- Stockwatch: two stocks for tough times?
- How to become a successful long-term investor
For investors, a highly uncertain economic outlook including rising interest rates could see some of its customers at least reduce some services or haggle harder over price. There's a risk that expected cost savings from Terminix might not be reached, while an estimated price/earnings (PE) ratio above the 10-year average suggests the shares are not obviously cheap.
More favourably, its core business of pest control is arguably essential and not a luxury in areas like hospitality. Bolt-on acquisitions continue and cost savings from its the Terminix acquisition are now being made.
On balance, and with the consensus analyst estimate of fair value standing at just over £6, reason for longer-term optimism appears to persist.
Positives:
- Diversity in both business type and geographical location
- Pest Control is a largely non-discretionary and essential service
Negatives:
- The weather can influence performance
- Currency movements can impact
The average rating of stock market analysts:
Buy
These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.
Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.